# Article information:

The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD‐L1
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816704/>

# Article summary:

1. Sunitinib, a multitargeted receptor tyrosine kinase inhibitor, can increase antitumor immunity and regulate tumor PD-L1 via p62-mediated selective autophagy.

2. Sunitinib shows a synergistic antitumor effect with cytotoxic T-lymphocyte-associated protein 4 monoclonal antibody in melanoma and NSCLC immune competent mice by promoting tumor-infiltrating lymphocytes activity.

3. A higher PD-L1 level but a lower p62 level in the tumor region of responders as compared to those of nonresponders among anti-PD-1-treated NSCLC patients is observed, providing a novel therapeutic strategy by the combination treatment of CTLA-4 with Sunitinib.

# Article rating:

Appears moderately imbalanced: The article provides some useful information, but is missing several important points or pieces of evidence that would be required to present the discussed topics in a balanced and reliable way. You are encouraged to seek a more balanced perspective on the presented issues by exploring the provided research topics and looking at different information sources.

# Article analysis:

该文章提出了Sunitinib在肿瘤免疫监视中通过调节肿瘤PD-L1的作用，但其存在一些潜在的偏见和不足之处。

首先，该文章没有探讨Sunitinib可能对其他免疫检查点的影响，而只关注了PD-L1。这可能导致对整个免疫系统的理解不够全面。

其次，该文章没有考虑到Sunitinib可能会对正常细胞产生负面影响。虽然该药物已被FDA批准用于治疗某些癌症，但它也有一些副作用，如高血压、心脏问题等。因此，在使用Sunitinib时需要谨慎考虑其风险和益处。

此外，该文章未提供足够的证据来支持其主张。尽管作者声称通过严格的计算分析、体外和体内功能特性表征以及新辅助临床试验揭示了一个新的分子机制，但并未提供详细数据或实验结果来支持这些主张。

最后，该文章似乎倾向于支持使用Sunitinib与CTLA-4单克隆抗体联合治疗。然而，并没有探讨其他可能的联合治疗方案，也没有提供足够的证据来支持这种治疗方法的优势。

综上所述，该文章存在一些潜在的偏见和不足之处，需要更全面地考虑其主张，并提供更多的证据来支持其结论。

# Topics for further research:

* Other immune checkpoints
* Potential negative effects on normal cells
* Lack of sufficient evidence
* Alternative combination therapies
* Potential biases and limitations
* Need for more comprehensive consideration and evidence

# Report location:

<https://www.fullpicture.app/item/1b97202c6203c208be333cf62a7da957>